Trenton, NJ - Gloucester County-based Akers Biosciences greatly expanded its global reach earlier this month when the China Food and Drug Administration (FDA) approved the company’s lead device PIFA® Heparin/PF4 Rapid Assay for use throughout Mainland China. Located in West Deptford, Akers Biosciences has spent over 25 years developing, manufacturing and supplying rapid screening and testing products -- known as “assays” -- designed to deliver quicker and more cost-effective healthcare data to healthcare providers and consumers.
The PIFA® Heparin/PF4 Rapid Assay checks to see if patients are allergic to the blood thinner Heparin by testing for the presence of a specific antibody associated with Heparin-Induced Thrombocytopenia (HIT), a specific type of blood clot. With the green light from the China FDA, Beijing-based pharmaceutical and medical device business development company Novotek will begin rolling out marketing of the testing devices to hospitals throughout China. At the end of September, Akers Biosciences announced that it signed distribution deals to market its proprietary testing device in India, German, Italy and Scandinavia.
According to Akers Biosciences Co-Founder and Executive Chairman Dr. Raymond Akers, Jr., the devices are also becoming more widely used in the United States where, he said, they remain the only United States FDA-cleared rapid manual assays that quickly determine if a patient being treated with heparin may be developing HIT. PIFA® Akers Biosciences stepped up the commercialization of Heparin/PF4 Rapid Assay this year.
“Millions of patients are exposed to heparin around the world each year and between one percent and five percent of those patients receive an HIT diagnosis,” Dr. Akers said. “Patients suffering from HIT are at risk of developing limb- and life-threatening complications, so the timely test results provided by PIFA® Heparin/PF4 devices are paramount to effective, clinical decision making.”
Akers Biosciences this week named John J. Gormally as its Chief Executive Officer. In announcing the appointment, Dr. Akers noted that Gormally, “previously helped successfully grow annual business revenues by more than $80 million in a business unit that contributed annual revenues of over $650 million. He led a multi-functional team of 92 associates including sales, marketing and finance teams.”
Akers Biosciences is among 41 companies to share more than $47 million through the State’s Technology Business Tax Certificate Transfer (NOL) Program in Fiscal Year 2016. Since the program’s inception in 1999, more than 500 technology and biotechnology companies have been approved for awards totaling $860 million.
“This innovative program enables biotechnology businesses like Akers Biosciences to sell New Jersey tax losses and/or research and development tax credits to raise cash to finance their growth and operations,” New Jersey Economic Development Authority Chief Executive Officer Melissa Orsen said. “It’s one more way we are fostering innovation and collaboration in the Garden State.”
@NJEDATech asked Dr. Akers about his company’s experience in New Jersey and its plans for the future:
Why did you choose to grow Akers Biosciences in New Jersey? I was born and raised in New Jersey, started my first business here, started this business here, and enjoy the benefits of being smack in the middle of the busiest economic corridor in the US. There is nowhere I would rather grow Akers Biosciences.
How has your company benefited from funding provided through the NOL program? We would not be here today without these funds. The NOL Program filled the gap of lean, early development years, and then provided much needed capital as we executed our go-to-market strategy.
What is Akers Biosciences’ biggest success to date? Our greatest success has been developing and introducing to the market the only rapid – and lifesaving - test in the world for an allergy to heparin.
What’s on the horizon for your company? We look forward to making the benefits of our products available to even more consumers globally. From our humble beginnings in West Deptford, Gloucester County, we have evolved into a net exporter of high tech medical products to 33 countries, including China. We are now listed on both the NASDAQ (AKER) and London (AKR) Stock Exchanges.
For more information about the State’s NOL program, visit http://www.njeda.com/nol and follow @NJEDATech onTwitter and LinkedIn.
According to Akers Biosciences Co-Founder and Executive Chairman Dr. Raymond Akers, Jr., the devices are also becoming more widely used in the United States where, he said, they remain the only United States FDA-cleared rapid manual assays that quickly determine if a patient being treated with heparin may be developing HIT. PIFA® Akers Biosciences stepped up the commercialization of Heparin/PF4 Rapid Assay this year.
“Millions of patients are exposed to heparin around the world each year and between one percent and five percent of those patients receive an HIT diagnosis,” Dr. Akers said. “Patients suffering from HIT are at risk of developing limb- and life-threatening complications, so the timely test results provided by PIFA® Heparin/PF4 devices are paramount to effective, clinical decision making.”
Akers Biosciences this week named John J. Gormally as its Chief Executive Officer. In announcing the appointment, Dr. Akers noted that Gormally, “previously helped successfully grow annual business revenues by more than $80 million in a business unit that contributed annual revenues of over $650 million. He led a multi-functional team of 92 associates including sales, marketing and finance teams.”
Akers Biosciences is among 41 companies to share more than $47 million through the State’s Technology Business Tax Certificate Transfer (NOL) Program in Fiscal Year 2016. Since the program’s inception in 1999, more than 500 technology and biotechnology companies have been approved for awards totaling $860 million.
“This innovative program enables biotechnology businesses like Akers Biosciences to sell New Jersey tax losses and/or research and development tax credits to raise cash to finance their growth and operations,” New Jersey Economic Development Authority Chief Executive Officer Melissa Orsen said. “It’s one more way we are fostering innovation and collaboration in the Garden State.”
@NJEDATech asked Dr. Akers about his company’s experience in New Jersey and its plans for the future:
Why did you choose to grow Akers Biosciences in New Jersey? I was born and raised in New Jersey, started my first business here, started this business here, and enjoy the benefits of being smack in the middle of the busiest economic corridor in the US. There is nowhere I would rather grow Akers Biosciences.
How has your company benefited from funding provided through the NOL program? We would not be here today without these funds. The NOL Program filled the gap of lean, early development years, and then provided much needed capital as we executed our go-to-market strategy.
What is Akers Biosciences’ biggest success to date? Our greatest success has been developing and introducing to the market the only rapid – and lifesaving - test in the world for an allergy to heparin.
What’s on the horizon for your company? We look forward to making the benefits of our products available to even more consumers globally. From our humble beginnings in West Deptford, Gloucester County, we have evolved into a net exporter of high tech medical products to 33 countries, including China. We are now listed on both the NASDAQ (AKER) and London (AKR) Stock Exchanges.
For more information about the State’s NOL program, visit http://www.njeda.com/nol and follow @NJEDATech onTwitter and LinkedIn.
